In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 77, No. 13_Supplement ( 2017-07-01), p. 4584-4584
Abstract:
The treatment of advanced non-small cell lung cancer (NSCLC) with PD-1 immune checkpoint inhibitors has improved clinical outcome for a proportion of patients. The current challenge is to find biomarkers that will identify patients likely to benefit from this therapy. In this study we assessed the difference of T cell subsets and PD-1 expression levels on T cells in tumor-draining lymph nodes (TDLN), non-TDLN (NTDLN) and peripheral blood mononuclear cells (PBMC). To evaluate this, flow cytometric analyses were performed on endobronchial ultrasound-guided (EBUS) fine-needle aspirates (FNA) from TDLN and NTDLN of patients with NSCLC and compared to PBMC. Our data show that the frequency of PD-1+ CD4+ and CD8+ T cells, as well as the PD-1 expression level on activated regulatory T (aTreg) and CD4+ and CD8+ T cells, are higher in TDLNs as compared to NTDLNs or PBMC. These elevated PD-1 expression levels in TDLN may reflect tumor-specific T cell priming and may serve as a predictive or early response biomarker during PD-1 checkpoint blockade. Citation Format: Rieneke Van De Ven, Anna-Larissa N. Niemeijer, Anita G. Stam, Sayed M. Hashemi, Christian G. Slockers, Johannes M. Daniels, Erik Thunnissen, Egbert F. Smit, Tanja D. de Gruijl, Adrianus J. de Langen. High PD-1 expression on regulatory and effector T cells in lung cancer draining lymph nodes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4584. doi:10.1158/1538-7445.AM2017-4584
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.AM2017-4584
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2017
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
Permalink